GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Daniela Darmanin: Passionate about people. Uncompromising about care.
What sits at the centre of Daniela's leadership is a genuine passion for the work itself.
Nicolas Chateau appointed Chief Commercial Officer at MedServRegis
MedservRegis provides integrated shore base logistics services to the offshore oil and gas industry.
‘Valletta’s main street needs to be turned into a luxury shopping destination’ – MHRA President
MHRA President speaks of need for less accommodation on the cheaper end of the market.
‘We need to bite the bullet on tourism’: the three institutional changes Malta needed yesterday
Embassy Hotels Malta General Manager Hubert Debono argues the country remains trapped in a self-perpetuating growth cycle - and three ...
